The effects of Elomumab on lipid metabolism in patients with hyperlipidemia and coronary heart disease who did not meet the standard of blood lipids after PCI
Aim To investigate the effects of Elomumab on lipid metabolism in patients with hyperlipidemia and coronary heart disease who have not yet reached blood lipid levels after percutaneous coronary intervention(PCI).Methods 72 patients with hyperlipidemia and coronary heart disease who did not achieve blood lipid levels after PCI were randomly divided into a control group(treated with basic statins)and an observation group(treated with basic statins combined with erlotinib).The treatment effi-cacy,lipid metabolism indicators before and after treatment,clinical endpoint events,and safety between two groups,were compared.Results The total effective rate of the observation group was higher than that of the control group(P＜0.05);After 3 months of treat-ment in both groups,high-density lipoprotein cholesterol levels were higher than those before treatment,and the observation group was higher than the control group(P＜0.05);Triglycerides,low-density lipoprotein cholesterol,and total cholesterol were lower than those before treatment,and the observation group was lower than the control group(P＜0.05);The readmission rate and incidence of myo-cardial infarction in the observation group with unstable angina pectoris were lower than those in the control group(P＜0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion Elomumab can improve lipid metabolism and reduce the risk of readmission and myocardial infarction in patients with hyperlipidemia and coronary heart disease who did not meet blood lipid standards after PCI.The efficacy is definite and does not increase adverse reactions.
万方数据
